NIS793X
Total Payments
$458,361
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $261,544 | 3 | 0 |
| 2017 | $196,817 | 4 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $458,361 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I IB OPEN LABEL MULTI CENTER DOSE ESCALATION STUDY OF NIS793 IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES | Novartis Pharmaceuticals Corporation | $458,361 | 0 |
Top Doctors Receiving Payments for NIS793X
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Salt Lake City, UT | $458,361 | 7 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $458,361
Product Information
- Type Drug
- Total Payments $458,361
- Total Doctors 0
- Transactions 7
About NIS793X
NIS793X is a drug associated with $458,361 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2018. In 2018, $261,544 was paid across 3 transactions to 0 doctors.
The most common payment nature for NIS793X is "Unspecified" ($458,361, 100.0% of total).
NIS793X is associated with 1 research study, including "A PHASE I IB OPEN LABEL MULTI CENTER DOSE ESCALATION STUDY OF NIS793 IN COMBINATION WITH PDR001 IN ADULT PATIENTS WITH ADVANCED MALIGNANCIES" ($458,361).